



14th October 2024

The Secretary,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 544250

The Secretary,
The National Stock Exchange of India Limited
C-1, Block G, Exchange Plaza
Bandra-Kurla Complex
Bandra East, Mumbai - 400 050
Symbol: SANOFICONR

Sub: Disclosure under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Dear Sir/Ma'am,

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, please find attached the disclosure received from Hoechst GmbH regarding change in holding of Securities of Promoter of the Company. The Company received this disclosure from Hoechst GmbH on 11th October 2024.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For **Sanofi Consumer Healthcare India Limited**

Nikunj Kumar Savaliya
Company Secretary and Compliance Officer
Membership No.: FCS 7048

Encl. a. a.



Date: 11 October 2024

To,

Sanofi Consumer Healthcare India Limited,
3rd Floor,
Sanofi House,
CTS No. 117-B, L&T Business Park,
Saki Vihar Road, Powai,
Mumbai – 400072

Re.: Disclosure under Regulation 7(2)(a) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (“PIT Regulations”).

Dear Sir / Ma’am,

This is in reference to the prior intimation made by Opella Healthcare Participations BV (“Opella”) to the stock exchanges (namely BSE Limited and National Stock Exchange of India) under Regulation 10(5) of the Takeover Relations on 3 October 2024 informing you about the proposed inter-se transfer of equity shares of Sanofi Consumer Healthcare India Limited (“SCHIL”), between Hoechst GmbH and Sanofi (existing promoters of SCHIL, collectively the “Sellers”) and Opella (“Acquirer”/“Buyer”), to be undertaken in one or more tranches.


In this connection, we now wish to inform you that, we, Hoechst GmbH, sold our shareholding of 1,39,04,722 equity shares in SCHIL (which represents 60.37% of the equity share capital of SCHIL) to Opella on 10 October 2024. The said inter-se transfer was undertaken on-market of the BSE Limited stock exchange.

Please find enclosed the disclosure in respect of the aforesaid sale.

Hoechst GmbH – A company of the sanofi-group
Chairman of the Supervisory Board: Brendan O’Callaghan
Managing Directors: Heidrun Irschik-Hadjieff, Marcus Lueger
Registered Place of Business: Frankfurt am Main – Commercial Register: Frankfurt am Main Abt. B Nr. 75707

sanofi

For and on behalf of Hoechst GmbH



Authorized Signatory

Name: Marcus Lueger

Designation: Managing Director

Date: 11 October 2024

Place: Frankfurt, Germany

Hoechst GmbH – A company of the sanofi-group
Chairman of the Supervisory Board: Brendan O'Callaghan
Managing Directors: Heidrun Irschik-Hadjieff, Marcus Lueger
Registered Place of Business: Frankfurt am Main – Commercial Register: Frankfurt am Main Abt. B Nr. 75707



SEBI (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7 (2) read with Regulation 6(2) – Continual Disclosure]

Name of the company: Sanofi Consumer Healthcare India Limited (“SCHIL”)

ISIN of the company: INE0UOS01011

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Name, PAN, CIN/DIN, & address with contact nos.	Category of Person (Promoter/member of the promoter group/designated person/Director s/immediate relative to/others etc.)	Securities held prior to acquisition/disposal		Securities acquired/Disposed				Securities held post acquisition/disposal		Date of allotment- advice/ acquisition—of shares/disposal of shares, specify		Date of intimation to company	Mode of acquisition/disposal (on-market/public/rights/preferential offer/off market/ Inter-se transfer, ESOPs, etc.)	Exchange on which the trade was executed
		Type of securities (For eg. – Shares, Warrant s, Convertible Debentures, Rights entitlements etc.)	No. and % of share holding	Type of securities (For eg. – Shares, Warrant s, Convertible Debentures, Rights entitlement, etc.)	No.	Value	Transaction Type (Purchase/sale / Pledge / Revocation / Invocation/ Others- please specify)	Type of securities (For eg. – Shares, Warrant, Convertible Debentures, Rights entitlement,	No. and % of share holding	From	To			

Hoechst GmbH – A company of the sanofi-group
 Chairman of the Supervisory Board: Brendan O’Callaghan
 Managing Directors: Heidrun Irschik-Hadjieff, Marcus Lueger
 Registered Place of Business: Frankfurt am Main – Commercial Register: Frankfurt am Main Abt. B Nr. 75707

sanofi

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Name: Hoechst GmbH ("Hoechst") PAN: AAACH1067P CIN: Not applicable Address: Brüningstraße 50, 65926 Frankfurt, Germany Contact No.: +49 69305821616	Promoter	Equity shares	1,39,04,722 (60.37%)	Equity shares	1,39,04,722 (60.37%)	69,274,020,240.10	Sale	Not Applicable ("N.A.")	Nil	10 October 2024	11 October 2024	11 October 2024	Inter-se transfer of equity shares (undertaken on-market) which is exempt from making an open offer under Regulation 10(1)(a)(iii) of the Securities and Exchange Board of India (Substantial Acquisition of Shares	BSE Limited

Hoechst GmbH - A company of the sanofi-group
 Chairman of the Supervisory Board: Brendan O'Callaghan
 Managing Directors: Heidrun Irschik-Hadjieff, Marcus Lueger
 Registered Place of Business: Frankfurt am Main - Commercial Register: Frankfurt am Main Abt. B Nr. 75707

sanofi

For and on behalf of Hoechst GmbH



Authorized Signatory

Name: Marcus Lueger

Designation: Managing Director

Date: 11 October 2024

Place: Frankfurt, Germany

Hoechst GmbH – A company of the sanofi-group

Chairman of the Supervisory Board: Brendan O'Callaghan

Managing Directors: Heidrun Irschik-Hadjieff, Marcus Lueger

Registered Place of Business: Frankfurt am Main – Commercial Register: Frankfurt am Main Abt. B Nr. 75707